Yuya Nakazawa

Title: Yuya Nakazawa: Innovator in Monoclonal Antibody Research

Introduction

Yuya Nakazawa is a prominent inventor based in Tokyo, Japan. He is known for his significant contributions to the field of monoclonal antibodies, particularly in the context of cancer research. His innovative work has the potential to impact therapeutic approaches for cancer treatment.

Latest Patents

Yuya Nakazawa holds a patent for "Mouse anti-Aggrus monoclonal antibodies." This invention provides a monoclonal antibody or a functional fragment capable of recognizing the Aggrus epitope, which includes specific amino-acid sequences. The patent also details the hybridoma associated with this invention, which has the accession numbers FERM BP-11446, FERM BP-11447, FERM BP-11448, and FERM BP-11449. Furthermore, the invention includes an Aggrus-CLEC-2 binding inhibitor and a pharmaceutical composition aimed at inhibiting platelet aggregation, preventing cancer metastasis, and treating tumors or cancer.

Career Highlights

Throughout his career, Yuya Nakazawa has worked with notable organizations, including the Japanese Foundation for Cancer Research and Lsip, LLC. His work in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Yuya Nakazawa has collaborated with esteemed colleagues such as Naoya Fujita and Satoshi Takagi. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in cancer treatment.

Conclusion

Yuya Nakazawa's contributions to monoclonal antibody research exemplify the importance of innovation in the medical field. His patent on anti-Aggrus monoclonal antibodies represents a significant advancement in cancer therapy.